Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ivosidenib

FDA-approved product (tablet, oral), marketed as Tibsovo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ivosidenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myeloid leukemia
  • Cholangiocarcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Isocitrate dehydrogenase (idh) inhibitors
FDA pharmacologic class
Isocitrate Dehydrogenase 1 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ivosidenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ivosidenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug-Drug Interaction Study of AG120 in Healthy Subjects

    NCT02831972 · start 2016-06

    Registered record
    Registry ID
    NCT02831972
    Conditions
    Healthy
    Interventions
    AG120; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06
    Completion
    2016-10
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAG120; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

    NCT02632708 · start 2015-12-31

    Registered record
    Registry ID
    NCT02632708
    Conditions
    Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); AML Arising From Antecedent Hematologic Disorder (AHD); AML Arising After Exposure to Genotoxic Injury
    Interventions
    AG-120; AG-221; cytarabine; daunorubicin; idarubicin; mitoxantrone; etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2015-12-31
    Completion
    2026-07-24
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNewly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); AML Arising From Antecedent Hematologic Disorder (AHD) +1 more
    InterventionAG-120; AG-221; cytarabine; daunorubicin +3 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Food Effect Study of AG120 in Healthy Subjects

    NCT02579707 · start 2015-10

    Registered record
    Registry ID
    NCT02579707
    Conditions
    Healthy
    Interventions
    AG120
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-10
    Completion
    2016-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAG120
    PhasePhase 1
    Registry statusCompleted

  • Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

    NCT02073994 · start 2014-03-01

    Registered record
    Registry ID
    NCT02073994
    Conditions
    Cholangiocarcinoma; Chondrosarcoma; Glioma; Other Advanced Solid Tumors
    Interventions
    AG-120
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03-01
    Completion
    2024-01-04
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholangiocarcinoma; Chondrosarcoma; Glioma; Other Advanced Solid Tumors
    InterventionAG-120
    PhasePhase 1
    Registry statusCompleted

  • Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

    NCT03245424

    Registered record
    Registry ID
    NCT03245424
    Conditions
    Acute Myeloid Leukemia; Relapsed Adult AML; Relapsed Pediatric AML
    Interventions
    ivosidenib (AG-120)
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Relapsed Adult AML; Relapsed Pediatric AML
    Interventionivosidenib (AG-120)
    PhaseNot recorded
    Registry statusApproved for marketing